Redmile Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Redmile Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.82M	Buy	+173,859	New	+$10.1M	0.65%	23
2023 Q3	–	Sell	-489,208	Closed	-$42.4M	–	69
2023 Q2	$42.4M	Buy	489,208 +154,038	+46%	+$14.5M	1.63%	18
2023 Q1	$32.6M	Buy	+335,170	New	+$34.7M	1.41%	24
2022 Q3	–	Sell	-300,000	Closed	-$24.9M	–	71
2022 Q2	$24.9M	Buy	+300,000	New	+$23.9M	0.95%	30
2019 Q3	–	Sell	-97,191	Closed	-$8.32M	–	77
2019 Q2	$8.32M	Buy	+97,191	New	+$8.31M	0.24%	61
2018 Q1	–	Sell	-2,500	Closed	-$223K	–	67
2017 Q4	$223K	Buy	+2,500	New	+$217K	0.01%	67
2016 Q3	–	Sell	-322,394	Closed	-$25.1M	–	53
2016 Q2	$25.1M	Sell	322,394 -155,893	-33%	-$13.3M	2.4%	16
2016 Q1	$39.4M	Buy	+478,287	New	+$38.9M	4.04%	8
2015 Q4	–	Sell	-368,775	Closed	-$38.8M	–	58
2015 Q3	$38.8M	Buy	368,775 +161,031	+78%	+$21.5M	2.94%	15
2015 Q2	$28.4M	Buy	+207,744	New	+$25.7M	2.33%	14
2014 Q4	–	Sell	-177,079	Closed	-$12.8M	–	57
2014 Q3	$12.8M	Sell	177,079 -291,021	-62%	-$19.1M	1.48%	31
2014 Q2	$29.1M	Buy	+468,100	New	+$28.3M	3.53%	9

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Redmile Group's BMRN Position: Q1 2026 in Review

Redmile Group opened a new position in BioMarin Pharmaceuticals (BMRN) in Q1 2026: 173,859 shares worth $9.82M. The stake represents 0.65% of the portfolio and ranks #23 among its holdings. This is a return to the name: Redmile Group previously reported a position in BMRN as recently as Q2 2023.

Redmile Group first reported a position in BMRN in Q2 2014 and has held it in 12 quarters since. The position peaked at $42.4M in Q2 2023. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Redmile Group held 173,859 shares of BioMarin Pharmaceuticals worth $9.82M as of Q1 2026.
BioMarin Pharmaceuticals was a new Redmile Group position in Q1 2026.
BioMarin Pharmaceuticals made up 0.65% of Redmile Group's portfolio in Q1 2026, its #23 holding.
Redmile Group first reported a position in BioMarin Pharmaceuticals in Q2 2014 and has held it in 12 quarters since.
Redmile Group's BioMarin Pharmaceuticals position peaked at $42.4M in Q2 2023.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Redmile Group's 13F filing for Q1 2026, filed 15 May 2026.